N/A N=156 A Mobile Informatics Solution to Aid in Memory
Alzheimer Disease · Dementia
Primary: PWMC Loneliness — 4.90; 5.28 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=87 Adalimumab in JIA-associated Uveitis Stopping Trial
Uveitis · JIA
Primary: Time to Treatment Failure — NA; 119 Time to treatment failure (days) — p=<0.0001
Phase 1 N=143 A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya
HIV Infections
Primary: Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) — 23; 27; 25; 10 Participants
Phase 2 N=448 Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Acute Respiratory Distress Syndrome · Coronavirus Infection
Primary: Number of Participants Who Are Classified 8 (Dead), 7 (Hospitalized, on Invasive Mechanical Ventilation or ECMO), or 6 (Hospitalized, on Non-invasive Ventilation or High…
Phase 3 N=261 Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Primary: Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose — -2.70; -2.61 Scores on a scale — p=0.7782
Phase 3 N=1,066 Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
COPD
Primary: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) — 0.248; 0.156; 0.138; -0.050 Litres — p=<0.001
Phase 1 N=54 A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
Multiple Sclerosis · Colitis, Ulcerative
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 3; 2; 6 Participants
Phase 1 N=8 Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
Transgender Health · Gender Dysphoria · Transgender Women
Primary: Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) — 17798.14; 18413.21 hr*ng/mL
Phase 2 N=17 Spironolactone Therapy In Young Women With NASH
NASH - Nonalcoholic Steatohepatitis
Primary: Change in Liver Stiffness on Magnetic Resonance Elastography (MRE) — 0.025; -0.265; 0.105; 0.135 Change in kPA
Phase 1 N=110 A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Gastrointestinal Neoplasms · Cholangiocarcinoma · Pancreatic Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BI 905711 in Phase 1a — NA milligram / kilogram (mg/kg)
Phase 1 N=20 Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
Tuberculosis
Primary: Assess Viable BCG Bacteria From Intradermal Challenge Site From Culture. — 20,440; 80; 5; 10,673 CFU
N/A N=29 Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study
Overweight and Obesity · PreDiabetes · Type 2 Diabetes
Primary: Change in BMI — 0.43; 0; 4.4; 0 kg/m2 — p=0.2
Phase 4 N=240 Carbetocin Myocardium Trial 2014 Part 2
Pregnancy Complications
Primary: Plasma Concentration Troponin I — 1.2; 1.2 ng/L — p=0.05
N/A N=39 Ericksonian Hypnosis Versus CBT for Prolonged Grief
Prolonged Grief Symptoms
Primary: Prolonged Grief Scale — 34; 21; 24; 26 points
Phase 2 N=233 A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Lipoprotein Disorder
Primary: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay — -47.35; -81.57; -85.71; 0.48 Percent change — p=<.001